Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 28 October 2025 - 5 November 2025

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

FDA Setback: Complete Response Letter Halts Lead Drug Ambitions Biohaven’s recent troubles center on VYGLXIA (troriluzole) – its lead drug candidate for spinocerebellar ataxia (SCA), a degenerative brain disorder that currently has no approved treatmentreuters.com. On November 4, 2025, after market close, Biohaven announced that the FDA had issued a Complete Response Letter (CRL) rejecting the company’s New Drug Application. This CRL cited multiple concerns with Biohaven’s data: potential bias, design limitations, lack of pre-specification, and unmeasured confounding factors in the supporting studiesstocktwits.comstocktwits.com. In simpler terms, the FDA was uneasy with how Biohaven ran and analyzed its trials – particularly
5 November 2025
·
Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Financial Health and Earnings Trends Teva’s financial turnaround appears to be gaining steam, driven by both top-line growth and disciplined cost management. Quarterly revenue has now grown year-over-year for 11 straight quartersinvesting.com, marking a sustained rebound after a difficult past decade. In Q3 2025, revenue rose ~3% YoY (1% in constant currency) to $4.48 Binvesting.com, while adjusted earnings jumped to $0.78 per share (from $0.69 a year ago)reuters.com. Notably, this beat Wall Street estimates by ~$0.10 and marked Teva’s strongest earnings surprise of 2025reuters.com. The growth engines are Teva’s newer branded drugs: movement-disorder treatment Austedo, migraine injection Ajovy, and schizophrenia depot
5 November 2025
··
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Once Sky-High Valuation Falters Amid Weight-Loss Drug Headwinds Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market valuereuters.com. The Danish pharmaceutical giant enjoyed surging sales as Wegovy and its type-2 diabetes sibling Ozempic (both containing the GLP-1 agonist semaglutide) became global sensations, with millions seeking their dramatic weight-loss benefits. However, 2025 has seen a sharp reversal of fortune. A “slew of headwinds has shaken investor confidence” in Novo Nordisk’s once-dominant growth storystockanalysis.com. The company’s share price has plummeted nearly 50% year-to-date amid signs
5 November 2025
·
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Background: Novo vs. Pfizer in the Weight-Loss Drug Race The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market sharereuters.com. Novo’s new CEO Mike Doustdar and the company’s controlling foundation have pushed for bolder moves after days of sliding market performancereuters.comreuters.com. In late October, Novo – which had already agreed a separate $5 billion deal to buy diabetes biotech Akero – suddenly “launched a bid…valuing [Metsera] at some $9 billion and crashing Pfizer’s deal”reuters.com. This was weeks after Novo’s top shareholder
4 November 2025
·
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Q3 Earnings Beat and Raised Outlook Pfizer delivered a positive surprise in Q3 2025, topping earnings and revenue expectations even as its overall results declined from a year ago. Adjusted earnings per share came in at $0.87, comfortably above consensus (~$0.63–$0.64)reuters.com. This was achieved on quarterly revenue of about $16.7 billion, which, while ~6% lower than the same period last year, slightly exceeded analysts’ forecasts (~$16.5B)stocktwits.comreuters.com. The decline was largely anticipated due to the sharp drop in COVID-19 product demand, but stronger-than-expected sales in other areas helped Pfizer beat the Street’s estimates. Encouraged by the quarter’s results, Pfizer raised its
4 November 2025
·
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Stock Price and Recent Performance Pfizer’s stock has languished in 2025 despite a rising broader market. At ~$24.65, PFE is roughly flat since January and far below its 2021 peak (~$50)sharewise.com. In the past three years, the shares have tumbled about 50% as the company’s COVID-fueled revenue boom faded and investors braced for patent expirationssharewise.com. By mid-2025, Pfizer traded near multi-year lows (around $23), though it bounced off those lows in early October after positive news on earnings and policy. Notably, Pfizer’s stock surged ~15% at the end of Q3 (from ~$23.85 on Sept. 29 to ~$27.37 by Oct. 3statmuse.comstatmuse.com)
3 November 2025
·
Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

RANI Stock Performance: From Penny Stock to Momentum Rocket Rani Therapeutics’ stock price has been on a tear in late 2025, turning heads in the biotech investing community. After languishing under $1 for most of the year, RANI exploded upward in October. It closed on Oct 31 at $2.20, up +51.7% in one dayfinviz.com on massive volume (~61 million shares vs ~15 million averagefinviz.com). In fact, over the past month RANI has climbed about 335%finviz.com. Just a few weeks ago in early October it was trading around 50–60 cents; by the first week of November it’s oscillating in the mid-$2s.
3 November 2025
·
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Company Background & Significance Founded in 1849, Pfizer Inc. has grown into a pillar of the pharmaceutical industry, known for landmark drugs and vaccines. From breakthrough treatments like Lipitor (cholesterol) and Viagra (ED), to its 2020 partnership with BioNTech delivering the first approved COVID-19 vaccine, Pfizer’s innovations have had global impact. Today the company employs about 81,000 people worldwide and operates 35+ manufacturing sitesxtalks.com. It was the world’s top drugmaker by sales during the pandemic boom (record revenue of $100 billion in 2022), and even with post-COVID declines Pfizer is expected to generate ~$62 billion in revenue in 2025 –
2 November 2025
Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Market Snapshot (pre-market Nov 3) As of Oct. 31 close, Eli Lilly (NYSE:LLY) was around $862–864 (with after-hours ~864) Stockanalysis Marketbeat. That’s up ~9–10% from early October Nasdaq. Trading volumes have been heavy, and LLY remains near its 52-week high (~$935) Marketbeat. MarketBeat notes LLY’s 50-day moving average is ~$780 Marketbeat, reflecting the recent surge. Institutional ownership is high (~82.5% by funds Marketbeat) and sentiment is bullish. Blowout Q3 & Raised Guidance Lilly’s Q3 (announced Oct 30) blew past forecasts. Revenue was $17.60 billion (+54% YoY) with EPS $7.02 Marketbeat, versus consensus ~$16.1 B/$5.9. Key GLP-1 drugs led the surge. The company
2 November 2025
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics Stock Explodes on Obesity-Drug Breakthrough – Analysts Eye $10+ Targets

Stock Performance and Recent Movement Rani shares have exploded in the last month. On Oct 1, 2025 RANI traded around $0.50. A landmark collaboration announced Oct 17 with Japan’s Chugai (up to $1.085B deal) and a simultaneous $60M financing sent the stock soaring. Intraday Oct 17 it jumped from $0.47 to $2.39 (+248%)ts2.tech. By Oct 31 the stock closed at $2.20, a 51.7% gain on that day alonets2.tech. This means RANI is up roughly +20% in the past week (from ~$1.82 on Oct 24 to $2.20) and about +330% in Octoberinvesting.cominvesting.com.This rally propelled RANI well above Nasdaq’s $1 minimum bid
1 November 2025
AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

Stock Performance & Technical Trends AbbVie’s stock has been a standout performer in 2025. Shares currently hover around $228–$229, up roughly 28–30% since January and near their highest levels on recordts2.techreportify.cn. This vastly outperforms both the S&P 500 (up ~16% YTD) and the broader pharma industry (up mid-single-digits)timesunion.comreportify.cn – a testament to investors’ optimism in AbbVie’s post-Humira strategy. The stock’s 52-week range spans from a low of about $163.8 to the recent peak around $244.8 on October 1stts2.tech. Several catalysts have fueled this rally. In mid-September, AbbVie announced a patent settlement securing no U.S. generics for Rinvoq until 2037, effectively
31 October 2025
··
Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Market Performance & Buyout Rumors On Oct. 30, 2025 Moderna’s stock jumped sharply. Midday trading saw MRNA up ~11.7% to about $27.56tradingview.com, reversing much of September–October’s slide. This followed a STAT News report (cited by Reuters) that Moderna has held buyout or partnership talks with at least one large drugmakertradingview.com. Moderna’s shares had been languishing near all-time lows (after falling roughly 90% from pandemic highs)tradingview.com, so today’s news sparked a relief rally. Even so, with the recent gain the stock remains roughly 37% below its Jan. 2025 pricetradingview.com. (By comparison, the Nasdaq and biotech indices were mostly flat today.) Moderna
30 October 2025
·
Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Stock Price & Recent Performance Pfizer’s stock has been rangebound in the low-to-mid $20s for much of 2025. By late September, PFE traded around $23.60 – about 9% below its price a year earlierts2.tech – as investors grappled with the end of Covid vaccine and treatment revenues. That all changed in early October. In the final trading week of September, Pfizer shares jumped ~15%, rallying from roughly $23.6 (Sept. 25) to about $27.2 by Oct. 1ts2.tech. This dramatic move was largely driven by two key announcements (see below) and marked one of PFE’s strongest weekly gains in years. After peaking
30 October 2025
·
Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000?

Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000?

October Stock Moves and Market Reaction Eli Lilly’s stock has moved sharply in recent weeks. After languishing around the mid-$700s in late September, the stock soared in early October. Between Sept. 29 and Oct. 1 it jumped over 9%, briefly touching the low $830s ts2.tech. Analysts noted this jump was fueled by a “perfect storm” of good news: better-than-expected trial results and anticipation of strong earnings. Trading volume was heavy, and by Oct. 23 shares were holding near $818 ts2.tech, about 6% higher on the year (roughly in line with the health-care index). The stock then saw a mid-month wobble.
30 October 2025
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo’s counter-offer details Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolioreuters.com. According to MarketScreener (Dow Jones Newswires), the bid is $56.50 in cash per Metsera share plus $21.25 in milestone CVRsmarketscreener.com. By contrast, Pfizer’s September deal was $4.9B upfront (about $28.50/share) plus CVRs, for up to ~$7.3Bts2.techreuters.com. Novo’s offer thus values the company at roughly $6.5B upfront, sweetened to ~$9B with earnouts. Novo’s CEO Maziar “Mike” Doustdar hailed the move as proof of the company’s ambition. In
30 October 2025
··
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Dips on Earnings Beat — Will Pipeline Boost Spur a Rally?

Merck’s stock price dipped on Oct 30, 2025 even as it delivered a strong third-quarter report. The company posted $17.28 B in Q3 sales and $2.58 adjusted EPS – above analyst forecastsmarketscreener.com. Sales of Keytruda, its blockbuster cancer drug, grew about 10% (to $8.1 B)marketscreener.com, offsetting a drop in Gardasil vaccine revenue. Despite the beat, Merck narrowed its 2025 sales outlook (now $64.5–65.0 B) while slightly raising profit guidancemarketscreener.com, a cautious stance that likely weighed on the share price. Pipeline and Drug Approvals Drive Hopes Beyond the quarterly numbers, recent product news is energizing Merck’s outlook. In September 2025 the FDA approved Keytruda
30 October 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock on Fire: GLP-1 Bonanza, Big Earnings & AI Pivot Drive Rally

LLY Stock Snapshot and Recent Moves Eli Lilly’s stock (NYSE: LLY) has been on a tear this year, driven by blockbuster drug sales and upbeat guidance. As of Oct. 29, 2025, LLY traded near $813.53investing.com. After hitting highs in the mid-$850s in early October, the shares have pulled back modestly (closing about 2% lower in the past week). Trading volume and technical indicators suggest a consolidation phase after the recent rallyintellectia.aiintellectia.ai. Over the past 12 months LLY has significantly outperformed the broader market, in large part thanks to its GLP-1 diabetes/obesity franchise. Wall Street now assigns it a Moderate Buy consensus;
30 October 2025
··
Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

ERNA Stock Soars on Cell Therapy Breakthrough Ernexa Therapeutics Inc. – a small Cambridge, MA biotech formerly known as Eterna Therapeutics – saw its stock skyrocket on October 29 after unveiling a major collaboration to advance its cutting-edge cancer therapy. By Wednesday afternoon, ERNA shares were up about 48% as investors piled in on news that Ernexa is partnering with Cellipont Bioservices to scale up ERNA-101 for clinical trialsstocktwits.com. “Shares of Ernexa Therapeutics (ERNA) traded 48% higher on Wednesday afternoon after Cellipont Bioservices announced that it has entered into a collaboration with the company,” Stocktwits reportedstocktwits.com. The stock, which had
29 October 2025
·
Regeneron Stock Rockets on Strong Q3, Dupixent Boom – Analysts See 27% Upside

Regeneron Stock Rockets on Strong Q3, Dupixent Boom – Analysts See 27% Upside

Key points: Regeneron (NASDAQ: REGN) shares recently traded around $580–$585 (closing at $585.31 on Oct 27) after a slight pullback earlier in the month investing.com. Over the past week REGN is up roughly 1–2%, recovering from a low in the high $570s investing.com. In its Oct. 28 earnings release, Regeneron reported Q3 2025 revenue of $3.75 billion (+1% y/y), led by a 27% jump in Dupixent (its eczema/asthma drug) to $4.86 billion stocktitan.net. The company also won FDA approval for Libtayo in a high-risk skin cancer indication (first-ever immunotherapy in that setting), and positive EU reviews for Libtayo and Dupixent stocktitan.net. Wall
28 October 2025
··
1 … 29 30 31 32 33 34

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Go toTop